Ozempic Thyroid Cancer Risk: The Boxed Warning Explained

Ozempic thyroid cancer risk is a real label warning but an unproven human effect. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) carry a boxed warning because they caused thyroid C-cell tumors in rodents. The labels say it is unknown whether they cause these tumors, including medullary thyroid carcinoma (MTC), in people. Large population studies from Scandinavia and from six countries and regions found no clear increase in thyroid cancer, while a French study found a higher risk after one to three years of use. The medicines must not be used by anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A neck lump, lasting hoarseness, trouble swallowing or shortness of breath should be reported to a clinician.

Peptide Labs does not sell Ozempic, Wegovy, Mounjaro, Zepbound or any prescription drug. This article summarizes FDA labels and published research. For how these medicines work, see our explainer on GLP-1 and the medicines that mimic it.

What the Ozempic boxed warning says

A boxed warning is the FDA’s most prominent label warning. The Ozempic boxed warning (prescribing information revised May 2026) states that semaglutide causes thyroid C-cell tumors in rodents, and that it is unknown whether Ozempic causes C-cell tumors, including MTC, in humans because the human relevance of the rodent findings has not been determined. The same warning appears on Wegovy (June 2026), Rybelsus and Ozempic tablets (January 2026), and Mounjaro and Zepbound (August 2026).

In lifetime studies in mice and rats, semaglutide increased C-cell adenomas (benign tumors) and carcinomas at exposures similar to those in people, and the effect grew with higher exposure and longer use. The tirzepatide labels describe the same finding in rats. The labels also note that cases of MTC have been reported after approval in people who used liraglutide, an older GLP-1 medicine, but say those reports are insufficient to establish or exclude a causal link.

What is medullary thyroid carcinoma?

The thyroid has two main cell types. Follicular cells make thyroid hormone and give rise to the most common thyroid cancers, such as papillary cancer. C cells make the hormone calcitonin and are the source of MTC, the cancer the boxed warning is about. The National Cancer Institute describes MTC as a neuroendocrine cancer and notes that it usually releases calcitonin into the blood.

According to the National Cancer Institute, about 25% of reported MTC cases are hereditary, most often as part of MEN 2A or MEN 2B, inherited conditions that can also cause adrenal and parathyroid tumors. That is why most questions about medullary thyroid carcinoma Ozempic risk come back to family history. If a parent, sibling or child has had MTC, or your family carries a MEN 2 diagnosis, tell your prescriber before starting any GLP-1 medicine.

GLP-1 thyroid cancer studies in people

Human evidence on GLP-1 thyroid cancer risk comes mainly from observational studies of people with type 2 diabetes. These studies can show associations but cannot prove cause, and they depend on how carefully they account for differences between groups.

The French study used national insurance records and found the higher risk in people who had used GLP-1 medicines for one to three years. The Scandinavian authors suggested that part of this signal could reflect detection bias: people starting a new diabetes medicine may have more check-ups and scans, so small thyroid cancers that would otherwise go unnoticed are found more often. The Scandinavian study’s upper confidence limit was consistent with no more than a 31% relative increase in risk.

All three studies have limits. Most person-time came from liraglutide; in the Scandinavian study semaglutide made up about a third of users, with an average follow-up of only about a year. Tirzepatide, approved in 2022, was barely represented. Thyroid cancers can take years to develop, and the multisite study notes its short follow-up cannot rule out a long-term risk. The MTC estimates are especially uncertain because MTC is rare.

Ozempic thyroid cancer risk: weighing the evidence

Based on current evidence, Ozempic thyroid cancer risk in people without a relevant family history appears small, if it exists at all, but it has not been excluded. The rodent finding is clear, the human data are mostly reassuring in the short term, and one well-designed study raised a signal that others have not confirmed. That is why the FDA keeps the boxed warning and the contraindication in place.

For context, the labels list other serious warnings that are better documented in people, including pancreatitis, gallbladder problems and kidney injury from dehydration. Our guides to semaglutide side effects and tirzepatide side effects cover them, and side effects across the GLP-1 class compares the class as a whole.

Thyroid symptoms to report and screening questions

The Ozempic, Wegovy, Mounjaro and Zepbound Medication Guides ask patients to tell their healthcare provider about:

• A lump or swelling in the neck.
• Hoarseness that does not go away.
• Trouble swallowing.
• Shortness of breath.

These symptoms have many possible causes, most of them not cancer, but they deserve a prompt check. The labels also say that routine blood calcitonin tests or thyroid ultrasounds are of uncertain value for catching MTC early in people on these medicines, and that routine screening may lead to unnecessary procedures because calcitonin tests are not very specific and thyroid nodules are common. If a calcitonin level is raised or a nodule is found on an exam or a scan, the labels advise further evaluation. Whether you need any thyroid testing is a decision for your clinician, based on your history and symptoms.

Questions to raise with your prescriber

• Has anyone in my family had medullary thyroid cancer, MEN 2, or thyroid surgery for an unclear reason?
• Do I have thyroid nodules or a thyroid condition that should be checked before starting?
• Which neck or swallowing symptoms should make me call you, and how quickly?
• How does the thyroid warning compare with my risks from diabetes or excess weight?

If you are also weighing semaglutide products against each other, our comparison of Wegovy and Ozempic explains the differences in approved uses. Questions about pregnancy planning on these medicines are covered in our guide to Ozempic and pregnancy.

Frequently Asked Questions

Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.

Last reviewed October 2026.

Related guides: Semaglutide Side Effects: What the Ozempic, Wegovy and Rybelsus Labels Say, GLP-1 Side Effects: What Every GLP-1 Drug Label Warns About, What Is GLP-1? The Hormone, How GLP-1 Drugs Work and Every FDA-Approved Option.